Sonic Healthcare- Support Range
Sonic Healthcare is under Algo Engine buy conditions. The underlying earnings remain strong and we expect buying support to build within the indicated range.

Sonic Healthcare is under Algo Engine buy conditions. The underlying earnings remain strong and we expect buying support to build within the indicated range.
Aristocrat Leisure is under Algo Engine buy conditions.
Sorry, but this content is restricted to our members.
Please login with your account or register for a free trial. If your trial has expired, then you may renew it here.
If you are having an issue with your account, then please get in touch with us.
ASX is under Algo Engine buy conditions.
Aristocrat Leisure is under Algo Engine buy conditions.
Xero is under Algo Engine buy conditions. Buying support is likely to build within the $86 to $96 price range.
1/3 Update:
Citigroup’s total exposure to Russia amounts to nearly $10 billion. Citigroup warned generally of a potential hit to its business from escalated tensions between the West and Russia following its invasion of Ukraine.
BlueScope Steel is under Algo Engine buy conditions.
With $285M of stock bought since August 2021, the Board has approved an increase in the scale of the buy-back program to allow up to a further $700 million to be bought over the next 12 months
BlueScope delivers record underlying EBIT of $2.20Bn, increases on-market buy-back; commences feasibility, analysis on blast furnace reline at Port Kembla
1H FY2022 Headlines
Reported NPAT: $1.64Bn
Underlying NPAT: $1.57Bn
Underlying EBIT: $2.20Bn
2H FY2022 GROUP OUTLOOK: Underlying EBIT in 2H FY2022 is expected to be in the range of $1.20 billion to $1.35 billion.
Qube Holdings is under Algo Engine buy conditions.
1H22 NPAT of $88 million was ahead of consensus expectations.
We see moderate levels of growth, supported by container volumes and ongoing strength in commodity demand, helping to underpin 3 – 4% EPS growth into FY23 & FY24.
Reece is under Algo Engine buy conditions. 1H22 result was above expectations, with underlying EBITDA increasing 14% to $397m. US performance was a key highlight and we expect 5 -7% EPS growth into FY23.
The stock trades on a forward yield of 1.5%.
Or start a free thirty day trial for our full service, which includes our ASX Research.